IsomAb

IsomAb is a biotechnology company developing isoform-specific antibody therapeutics for serious vascular diseases.

Its lead programme, ISM-001, targets VEGF-A165b, an anti-angiogenic splice isoform implicated in peripheral arterial disease and chronic limb-threatening ischaemia.

The company uses a bioinformatics-guided platform to identify pathogenic mRNA splicing targets and develop disease-modifying antibodies for conditions with limited treatment options. ISM-001 is currently in IND-enabling preclinical studies.